← Browse by Condition
Medical Condition

nasopharyngeal carcinoma npc

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for nasopharyngeal carcinoma npc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — nasopharyngeal carcinoma npc Clinical Trials

How many clinical trials are currently recruiting for nasopharyngeal carcinoma npc?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for nasopharyngeal carcinoma npc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for nasopharyngeal carcinoma npc?
nasopharyngeal carcinoma npc research spans Phase 2 (2 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a nasopharyngeal carcinoma npc clinical trial?
Eligibility criteria for nasopharyngeal carcinoma npc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Phase 3
2
Top Sponsors
Man Hu 1 trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 1 trial
Hongmeng Yu 1 trial
Ming-Yuan Chen 1 trial
Nanfang Hospital, Southern Medical University 1 trial

Recruiting Clinical Trials

NCT07340515 Phase 3
Recruiting
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Enrollment
300 pts
Location
China
Sponsor
Man Hu
View Trial →
NCT07618078
Recruiting
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
Enrollment
900 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT07781358 Phase 2
Recruiting
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Enrollment
25 pts
Location
China
Sponsor
Hongmeng Yu
View Trial →
NCT07328841 Phase 3
Recruiting
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
Enrollment
456 pts
Location
China
Sponsor
Ming-Yuan Chen
View Trial →
NCT07819656
Recruiting
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
Enrollment
1,782 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med...
View Trial →
NCT07101744 Phase 2
Recruiting
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Enrollment
41 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →

Related Conditions

myelosuppression (1) first line treatment failure nasopharyngeal carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology